Novartis

Portfolio Co Investors 2026 for Novartis: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Novartis accounts for 22 tracked companies with verified cap-table data, 22 of which disclose round sizes totalling $3B. The median disclosed raise is $115M, and the largest is Proteus Digital Health at $400M, ahead of Poseida Therapeutics ($313M) and Flare Therapeutics ($287M).

The names that recur most often on these co-invested cap tables are Novartis (22 companies), Invus (3 companies), GV (3 companies), Third Rock Ventures (2 companies), Nextech Invest (2 companies), Pfizer Ventures (2 companies). By latest disclosed round, the market skews Series C (6), Series B (4), Growth (3), Series A (3).

Best funded Novartis companies

  1. Proteus Digital Health — $400M
  2. Poseida Therapeutics — $313M (latest: Series B)
  3. Flare Therapeutics — $287M (latest: Series C)
  4. Science 37 — $235M (latest: Series D)
  5. Rani Therapeutics — $202M (latest: Growth)
  6. ESCAPE Bio — $184M (latest: Series C)
  7. Alladapt Immunotherapeutics — $179M (latest: Series C)
  8. Borealis Biosciences — $150M (latest: Series A)
  9. Expansion Therapeutics — $135M (latest: Series B)
  10. Credence MedSystems — $123M (latest: Series D)
  11. Akebia Therapeutics — $115M (latest: IPO)
  12. Mersana Therapeutics — $85M (latest: Series C)
  13. Orionis Biosciences — $85M (latest: Series C)
  14. Ribon Therapeutics — $75M (latest: Series B)
  15. Koneksa Health — $65M (latest: Series C)

Novartis Services Inc — related firms and companies (56)

Novartis Services Inc profile · All research reports